香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 茲提述本公司日期為2025年4月28日 及2025年4月29日 的 公 告（「該等公告」），內 容有關收購目標公司100%已 發 行 股 份，以 此 拓 展 人 工 智 能(AI)骨健康診斷業務 和 檢 測 機 器 人。本 集 團 正 在 準 備 向 聯 交 所 提 交 審 閱 的 通 函 文 件，以 期 儘 快 完 成 收 購。 關 於 骨 健 康 領 域「智 慧 健 康 管 理」業 務 進 展 本集團在2025年5月 與 中 國 某 間 國 營 公 司 合 作 啟 動 了 籌 建 智 慧 健 康 管 理 中 心， 該 業 務 將 為 客 戶 提 供 定 制 化 健 康 管 理 服 務。 – 1 – 本 公 司 一 直 積 極 ...

Core Viewpoint - The company, Haiwang Bio, has announced the termination of its control change and private placement plan, marking the end of a capital cooperation that was initiated in early 2024 [2][8]. Group 1: Background of Control Change and Private Placement - The control change and private placement plan began on January 13, 2024, when Haiwang Bio and its controlling shareholder, Haiwang Group, signed a cooperation agreement with Sifang Group to transfer part of the shares [5]. - On July 28, 2024, a share transfer agreement was signed, where Sifang Group was to acquire 315.7 million unrestricted shares from Haiwang Group, representing 12% of Haiwang Bio's total shares [5][6]. - To ensure the smooth transfer of control, a voting rights waiver agreement was signed, where Haiwang Group would relinquish voting rights for 900.7 million shares, effectively transferring control to Sifang Group [5][6]. Group 2: Termination of Agreements - On June 6, 2025, the capital cooperation was abruptly terminated, with Haiwang Bio, Haiwang Group, and Sifang Group signing a termination agreement [8]. - The termination was described as a "no-fault termination," indicating that it was a result of amicable negotiations, with no party liable for breach of contract [8]. - Haiwang Group is required to return a deposit of 10 million yuan to Sifang Group within five days of the termination agreement's effectiveness [8]. Group 3: Impact of Termination - Following the termination, Haiwang Bio stated that there would be no change in its controlling shareholder or actual controller, and business operations would continue as normal [11]. - The company expressed regret for any inconvenience caused to investors and emphasized its commitment to focusing on core business areas, particularly in medical devices [11]. - Haiwang Bio indicated that it would continue to seek potential partnerships with state-owned enterprises for future equity cooperation opportunities [11]. Group 4: Financial Performance - In the first quarter of 2025, Haiwang Bio reported a revenue of 7.38 billion yuan, a year-on-year decrease of 8.8%, and a net profit attributable to shareholders of 23.72 million yuan, down 44.4% year-on-year [12]. - As of June 6, 2025, the company's stock price closed at 2.56 yuan per share, with a total market capitalization of 6.736 billion yuan [13].